Allena Pharmaceuticals’ (ALNA) Buy Rating Reiterated at Cowen

Cowen restated their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research note issued to investors on Friday, AnalystRatings.com reports.

Several other equities analysts have also issued reports on ALNA. Zacks Investment Research raised Allena Pharmaceuticals from a hold rating to a buy rating and set a $7.00 target price on the stock in a research note on Wednesday, May 8th. B. Riley set a $22.00 target price on Allena Pharmaceuticals and gave the stock a buy rating in a research note on Friday, March 8th. Wedbush reissued a buy rating and set a $39.00 target price on shares of Allena Pharmaceuticals in a research note on Sunday, March 10th. Finally, Robert W. Baird assumed coverage on Allena Pharmaceuticals in a research note on Friday, January 18th. They set an outperform rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $22.17.

ALNA opened at $5.21 on Friday. Allena Pharmaceuticals has a 12-month low of $4.80 and a 12-month high of $16.83. The company has a current ratio of 11.19, a quick ratio of 11.19 and a debt-to-equity ratio of 0.20. The stock has a market cap of $112.74 million, a P/E ratio of -3.03 and a beta of 1.69.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.06). Equities analysts forecast that Allena Pharmaceuticals will post -1.88 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Sphera Funds Management LTD. increased its holdings in Allena Pharmaceuticals by 16.9% during the 4th quarter. Sphera Funds Management LTD. now owns 345,199 shares of the company’s stock worth $1,881,000 after purchasing an additional 50,000 shares during the period. Vanguard Group Inc. increased its holdings in Allena Pharmaceuticals by 2.2% during the 3rd quarter. Vanguard Group Inc. now owns 349,819 shares of the company’s stock worth $3,757,000 after purchasing an additional 7,400 shares during the period. Fosun International Ltd purchased a new stake in Allena Pharmaceuticals during the 4th quarter worth about $154,000. BlackRock Inc. increased its holdings in Allena Pharmaceuticals by 1.7% during the 3rd quarter. BlackRock Inc. now owns 577,443 shares of the company’s stock worth $6,201,000 after purchasing an additional 9,736 shares during the period. Finally, Vanguard Group Inc increased its holdings in Allena Pharmaceuticals by 2.2% during the 3rd quarter. Vanguard Group Inc now owns 349,819 shares of the company’s stock worth $3,757,000 after purchasing an additional 7,400 shares during the period. Institutional investors own 80.07% of the company’s stock.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Recommended Story: What are the economic characteristics of a bear market?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.